Speaker: John Charpentier, Ph.D, Business Development Manager, Biocytogen Boston

• Introduced Biocytogen’s highly immunodeficient B-NDG mouse model
• Discussed our latest, next-generation B-NDG-derived models, such as the B-NDG β2m KO, B-NDG HLA-A2.1, and B-NDG hSIRPα/hCD47 models
• Described how B-NDG models recapitulate critical aspects of human biology, making them a powerful tool for biomedical research